Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Fulminant myocarditis / / Dao Wan Wang, editor
| Fulminant myocarditis / / Dao Wan Wang, editor |
| Pubbl/distr/stampa | Beijing ; ; Singapore : , : Science Press : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (375 pages) |
| Disciplina | 616.079 |
| Soggetto topico |
Immune response - Regulation
Myocarditis |
| ISBN |
9789811957598
9789811957581 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Foreword -- Foreword -- Foreword -- Preface -- Contents -- Contributors -- 1: Introduction: Accumulating More Knowledge and Ability in Treating Fulminant Myocarditis to Save More Lives -- References -- 2: The Epidemiology of Fulminant Myocarditis -- 2.1 Introduction -- 2.2 The Incidence of Fulminant Myocarditis -- 2.3 The Prognosis of Patients with Fulminant Myocarditis -- References -- 3: Pattern Recognition Receptors and Fulminant Myocarditis -- 3.1 Brief Introduction -- 3.2 Pattern Recognition Receptors (PRRs) -- 3.2.1 Membrane-Bound TLRs -- 3.2.2 TLR1-2 and TLR6 -- 3.2.3 TLR4 -- 3.2.4 TLR5 -- 3.2.5 TLR3 and TLR7-9 -- 3.2.6 TLR10 -- 3.2.7 NLRs -- 3.2.8 NLRP3 Inflammasome -- 3.2.9 RLRs -- 3.2.10 Cytoplasmic DNA Sensors -- 3.2.11 CLRs -- 3.2.12 Non-pattern Recognition Receptors -- 3.2.13 RAGE -- 3.2.14 PRMs -- 3.2.15 Myeloid Cells's Triggering Receptors -- 3.2.16 G-Protein-Coupled Receptors -- 3.2.17 Actions of PRRs -- 3.2.18 Phagocytosis and TLRs -- 3.2.19 TLR Signaling Pathways -- 3.3 Pyroptosis and its Pathway -- 3.3.1 Expression of PRRs and Responses to Ligands in Heart -- References -- 4: Etiology and Pathogenesis of Fulminant Myocarditis -- 4.1 Etiology of Fulminant Myocarditis -- 4.1.1 Infectious Factors -- 4.1.1.1 Enterovirus -- 4.1.1.2 Adenovirus -- 4.1.1.3 Parvovirus -- 4.1.1.4 Human Herpes Virus -- 4.1.2 Non-infectious Factors -- 4.2 Pathogenesis of FM -- 4.3 Laboratory Test -- 4.3.1 Enterovirus -- 4.3.2 Adenovirus -- 4.3.3 Parvovirus -- 4.3.4 Human Herpes Virus -- 4.3.4.1 Enzyme-Linked Immunosorbent Assay -- 4.3.4.2 Flow Cytometry -- 4.3.4.3 Liquid Cytokine Chip -- 4.4 COVID-19 Pandemic-Related Etiology -- References -- 5: Pathophysiology and Mechanisms of Fulminant Myocarditis -- 5.1 Animal Models of Fulminant Myocarditis -- 5.1.1 Mouse Selection -- 5.1.2 Virus Selection.
5.1.2.1 Modeling Method -- 5.1.3 Establishment and Evaluation of Common Animal Models of Fulminant Myocarditis -- 5.2 Cytokine Storm in Fulminant Myocarditis -- 5.2.1 Interferons -- 5.2.1.1 Type I Interferon (IFN I) -- 5.2.1.2 Type II Interferon (IFN II) -- 5.2.2 Interleukins -- 5.2.2.1 IL-1 Family -- 5.2.2.2 IL-2 -- 5.2.2.3 IL-6 Family -- 5.2.2.4 IL-10 -- 5.2.3 Chemokines -- 5.2.4 Tumor Necrosis Factor -- 5.3 Pathogenesis of Cytokine Storm in Fulminant Myocarditis -- 5.4 Possible Mechanisms of Cytokine Storm-Induced Cardiac Dysfunction -- 5.5 In the Future -- References -- 6: Pathology of Fulminant Myocarditis -- 6.1 Overview of the Pathology of Myocarditis and Fulminant Myocarditis -- 6.1.1 Infectious Myocarditis -- 6.1.2 Non-infectious Myocarditis -- 6.2 Pathological Characteristics of Myocarditis of Different Etiologies -- 6.2.1 Viral Myocarditis -- 6.2.2 Bacterial Myocarditis -- 6.2.3 Fungal Myocarditis -- 6.2.4 Systemic Disease-Associated Myocarditis -- 6.2.5 Granulomatous Myocarditis -- 6.2.6 Allergic Myocarditis -- 6.2.7 Toxic Myocarditis from Snake Venom -- 6.3 Typical Cases -- 6.3.1 Case 1 -- 6.3.2 Case 2 -- 6.3.3 Case 3 -- 6.3.4 Case 4 -- 6.3.5 Case 5 -- References -- 7: Clinical Manifestations of and Laboratory Tests for Myocarditis and Fulminant Myocarditis -- 7.1 Clinical Manifestations -- 7.1.1 Predisposing Factors -- 7.1.2 Early Symptoms -- 7.1.2.1 Respiratory Symptoms -- 7.1.2.2 Gastrointestinal Symptoms -- 7.1.2.3 Systemic Symptoms -- 7.1.2.4 Symptoms of Myocardial Damage -- 7.1.3 Progressive Symptoms -- 7.1.3.1 Symptoms of Myocardial Damage -- Chest Pain and Tightness -- Painless Myocarditis -- Arrhythmia -- 7.1.3.2 Hemodynamic Disorder -- Acute Heart Failure -- Cardiogenic Shock -- Adams-Stokes Syndrome -- 7.1.3.3 Manifestations of Multiple Organ Involvement -- 7.2 Physical Signs. 7.2.1 Vital Signs -- 7.2.1.1 Fever -- 7.2.1.2 Hypotension -- 7.2.1.3 Breathing Changes -- 7.2.1.4 Heart Rate and Heart Rhythm Changes -- 7.2.2 Heart-Related Signs -- 7.2.2.1 Cardiac Size -- 7.2.2.2 Heart Sounds and Murmurs -- 7.2.2.3 Cardiac Insufficiency -- 7.2.3 Lung Signs -- 7.3 Laboratory Examination -- 7.3.1 Myocardial Injury Marker Cardiac Troponin I or T (cTnI or cTnT) Assessment -- 7.3.2 Brain Natriuretic Peptide (BNP) Assessment -- 7.3.3 Blood Routine Examination -- 7.3.4 General Biochemical Tests -- 7.3.5 Coagulation Function Tests -- 7.3.6 Inflammatory Indicator Assessment -- 7.3.7 Pathogen Detection -- 7.3.8 ECG -- 7.4 Case Reports -- References -- 8: Diagnostic Values and Clinical Application of Endomyocardial Biopsy in Fulmiant Myocarditis -- 8.1 EMB -- 8.1.1 Preoperative Preparation -- 8.1.2 Approach Selection and Equipment Preparation -- 8.1.3 Several Common EMB Operation Processes -- 8.1.3.1 Transradial Left Ventricular EMB -- 8.1.3.2 Transfemoral Left Ventricular EMB -- 8.1.3.3 Transfemoral Right Ventricular EMB -- 8.2 Management and Analysis of Myocardial Intimal Tissue -- 8.2.1 Light Microscopic Examination and Staining of Myocardial Intimal Tissues -- 8.2.2 Molecular Study of Myocardial Intimal Tissue -- 8.2.3 Molecular Biological Detection of the Virus Genome in Myocardium Tissue -- 8.2.4 Immunohistochemistry of the Myocardium -- 8.3 Clinical Application of EMB in Fulminant Myocarditis -- References -- 9: Association between Histological Changes and Clinical Manifestations of Fulminant Myocarditis -- 9.1 Lymphocytic Myocarditis -- 9.1.1 Stage 0 (Pre-Infection Stage) -- 9.1.2 Stage 1 (Acute Stage) -- 9.1.2.1 Entry of Virus into Cardiomyocytes -- 9.1.2.2 Replication of Virus -- 9.1.2.3 Direct Viral Damage to Cardiomyocytes -- 9.1.2.4 Host Defense-Innate Immune Response -- Interferons -- TLRs. RNA Helicases -- 9.1.2.5 Host Defense-Acquired Immune Response -- 9.1.2.6 Damage to Host Cells by Host Immune Response -- 9.1.3 Stage 2 (Subacute Stage) -- 9.1.4 Stage 3 (Chronic Stage) -- 9.2 Giant Cell Myocarditis -- 9.3 Eosinophilic Myocarditis -- 9.4 Sarcoidosis Myocarditis -- 9.5 Connective Tissue Disease-Induced Autoimmune Myocarditis -- 9.6 Immune Checkpoint Inhibitor-Induced Myocarditis -- References -- 10: Changes of Electrpcardiography in Patients with Fulminant Myocarditis -- 10.1 Mechanism of Arrhythmias in Viral Myocarditis -- 10.2 Common ECG Findings of Fulminant Myocarditis -- 10.2.1 Sinus Arrhythmia -- 10.2.2 Atrial Arrhythmia -- 10.2.3 Changes in the Cardiac Conduction System -- 10.3 Arrhythmias and Prognosis of Myocarditis -- References -- 11: Echocardiography in Fulminant Myocarditis -- 11.1 Introduction -- 11.2 Two-Dimensional Echocardiography -- 11.2.1 Left Ventricular (LV) Function -- 11.2.2 Left Ventricular Dimension and Wall Thickness -- 11.2.3 Right Ventricular (RV) Function -- 11.2.4 Pericardial Effusion and Intra-cardiac Thrombus -- 11.3 Speckle-Tracking Echocardiography (STE) -- 11.4 Proposed Echocardiographic Scan Protocols -- 11.5 Utility of Echocardiography in Treating FM with Extracorporeal Membrane Oxygenation (ECMO) -- 11.6 Prognostic Value of Echocardiographic Measurements in FM -- 11.7 Conclusions -- References -- 12: Cardiac Magnetic Resonance in Fulminant Myocarditis -- 12.1 Introduction -- 12.2 Utility of CMRI in Acute Myocarditis -- 12.3 Lake Louise Criteria (LCC) -- 12.4 Novel CMR Mapping Techniques -- 12.5 Functional Abnormalities -- 12.6 Pericardial Abnormalities -- 12.7 Update to the LCC -- 12.8 Utility of CMRI in FM -- 12.9 Prognostic Value of CMRI in Myocarditis -- 12.10 Limitations of CMRI in FM -- 12.11 Conclusion -- References. 13: Diagnosis and Differential Diagnosis of Fulminant Myocarditis -- 13.1 Clinical Diagnosis of Fulminant Myocarditis -- 13.2 Pathological Classification of Fulminant Myocarditis -- 13.3 Differential Diagnosis of Fulminant Myocarditis -- References -- 14: Novel Conceptions in Treatments of Fulminant Myocarditis -- 14.1 New Understanding of Pathophysiology of Fulminant Myocarditis -- 14.2 Design of Treatment Regimen -- 14.3 Treatment Regimen -- 14.4 Life Support Treatment -- 14.4.1 ECMO -- 14.4.2 IABP -- 14.4.3 Percutaneous Left Ventricular Assist Device -- 14.5 Immunomodulatory Therapy -- 14.5.1 Intravenous Gamma Globulin -- 14.5.2 GCs -- 14.5.3 Cytotoxic Immunosuppressive Drugs -- 14.5.4 CRRT -- 14.6 Antiviral Treatment -- References -- 15: Treatments of Fulminant Myocarditis in Acute Phase -- 15.1 Treatment in Acute Phase: Core Treatments -- 15.2 Mechanical Circulation Support -- 15.3 Immunomodulation Therapy -- 15.4 Administration of Neuraminidase Inhibitors and Antiviral Drugs -- 15.5 Assessment of Treatment Effects -- 15.6 Auxiliary Care -- References -- 16: Prevention and Treatment of Arrhythmias Complicated by Fulminant Myocarditis -- 16.1 Prediction and Prevention of Lethal Arrhythmias -- 16.1.1 Hypotension -- 16.1.2 Usage of Catecholamines -- 16.1.3 Long-Term Usage of α-Receptor Agonists -- 16.1.4 Sustained Shock -- 16.1.5 Prolonged QRS Interval -- 16.1.6 Female Patients -- 16.1.7 Hypokalemia -- 16.1.8 Hypoxemia -- 16.2 Treatments to Bradyarrhythmia -- 16.2.1 Drug Treatment -- 16.2.2 Temporary Pacemaker -- 16.3 Tachycardia -- 16.3.1 Electrolytes Management -- 16.3.2 Monitor the QTc Interval -- 16.3.3 Anti-arrhythmia Drugs -- 16.3.4 Electrical Cardioversion -- 16.3.5 Electrical Storms -- 16.3.6 Traditional Chinese Medicine -- References. 17: Prevention and Treatment of Disseminated Intravascular Coagulation in Fulminant Myocarditis. |
| Record Nr. | UNINA-9910624314903321 |
| Beijing ; ; Singapore : , : Science Press : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Generation and effector functions of regulatory lymphocytes [[electronic resource] /] / [editors, Gregory Bock and Jamie Goode]
| Generation and effector functions of regulatory lymphocytes [[electronic resource] /] / [editors, Gregory Bock and Jamie Goode] |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, c2003 |
| Descrizione fisica | 1 online resource (327 p.) |
| Disciplina | 571.96 |
| Altri autori (Persone) |
BockGregory
GoodeJamie |
| Collana | Novartis Foundation symposium |
| Soggetto topico |
Lymphocytes
T cells Immune response - Regulation |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-280-27406-9
9786610274062 0-470-87161-X 0-470-87162-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
GENERATION AND EFFECTOR FUNCTIONS OF REGULATORY LYMPHOCYTES; Contents; Participants; Chair's introduction; Thymic generation and selection of CD25(+)CD4(+) regulatory T cells: implications of their broad repertoire and high self-reactivity for the maintenance of immunological self-tolerance; Discussion; Control of T cell activation by CD4(+)CD25(+) suppressor T cells; Discussion; Regulation of experimental autoimmune encephalomyelitis (EAE) by CD4(+)CD25(+) regulatory T cells; Discussion; The role of CD28 and CTLA4 in the function and homeostasis of CD4(+)CD25(+) regulatory T cells
DiscussionCD4(+)CD25(+) regulatory cells from human peripheral blood express very high levels of CD25 ex vivo; Discussion; Control of immune pathology by regulatory T cells; Discussion; General discussion I TGFB; Type 1 T regulatory cells and their relationship with CD4(+)CD25(+) T regulatory cells; Discussion; (PRO)insulin-specific regulatory T cells; Discussion; CD1d-restricted NKT regulatory cells: functional genomic analyses provide new insights into the mechanisms of protection against Type 1 diabetes; Discussion Seven surprises in the TCR-centred regulation of immune responsiveness in an autoimmune systemDiscussion; Regulatory cells in transplantation; Discussion; CD4(+) regulatory T cells in chronic viral infection; Discussion; General discussion II; Modulation of T cell responses after cross-talk between antigen presenting cells and T cells: a give-and-take relationship; Discussion; Dendritic cells: controllers of the immune system and a new promise for immunotherapy; Discussion; Regulation of viral and autoimmune responses; Discussion; General discussion III Active immune regulation Notch signalling in the peripheral immune systemDiscussion; CD3 antibody treatment stimulates the functional capability of regulatory T cells; Discussion; The role of dendritic cells in regulating mucosal immunity and tolerance; Discussion; Index of contributors; Subject index |
| Record Nr. | UNINA-9910143227103321 |
| Hoboken, N.J., : Wiley, c2003 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Generation and effector functions of regulatory lymphocytes [[electronic resource] /] / [editors, Gregory Bock and Jamie Goode]
| Generation and effector functions of regulatory lymphocytes [[electronic resource] /] / [editors, Gregory Bock and Jamie Goode] |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, c2003 |
| Descrizione fisica | 1 online resource (327 p.) |
| Disciplina | 571.96 |
| Altri autori (Persone) |
BockGregory
GoodeJamie |
| Collana | Novartis Foundation symposium |
| Soggetto topico |
Lymphocytes
T cells Immune response - Regulation |
| ISBN |
1-280-27406-9
9786610274062 0-470-87161-X 0-470-87162-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
GENERATION AND EFFECTOR FUNCTIONS OF REGULATORY LYMPHOCYTES; Contents; Participants; Chair's introduction; Thymic generation and selection of CD25(+)CD4(+) regulatory T cells: implications of their broad repertoire and high self-reactivity for the maintenance of immunological self-tolerance; Discussion; Control of T cell activation by CD4(+)CD25(+) suppressor T cells; Discussion; Regulation of experimental autoimmune encephalomyelitis (EAE) by CD4(+)CD25(+) regulatory T cells; Discussion; The role of CD28 and CTLA4 in the function and homeostasis of CD4(+)CD25(+) regulatory T cells
DiscussionCD4(+)CD25(+) regulatory cells from human peripheral blood express very high levels of CD25 ex vivo; Discussion; Control of immune pathology by regulatory T cells; Discussion; General discussion I TGFB; Type 1 T regulatory cells and their relationship with CD4(+)CD25(+) T regulatory cells; Discussion; (PRO)insulin-specific regulatory T cells; Discussion; CD1d-restricted NKT regulatory cells: functional genomic analyses provide new insights into the mechanisms of protection against Type 1 diabetes; Discussion Seven surprises in the TCR-centred regulation of immune responsiveness in an autoimmune systemDiscussion; Regulatory cells in transplantation; Discussion; CD4(+) regulatory T cells in chronic viral infection; Discussion; General discussion II; Modulation of T cell responses after cross-talk between antigen presenting cells and T cells: a give-and-take relationship; Discussion; Dendritic cells: controllers of the immune system and a new promise for immunotherapy; Discussion; Regulation of viral and autoimmune responses; Discussion; General discussion III Active immune regulation Notch signalling in the peripheral immune systemDiscussion; CD3 antibody treatment stimulates the functional capability of regulatory T cells; Discussion; The role of dendritic cells in regulating mucosal immunity and tolerance; Discussion; Index of contributors; Subject index |
| Record Nr. | UNINA-9910830549003321 |
| Hoboken, N.J., : Wiley, c2003 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Generation and effector functions of regulatory lymphocytes / / [editors, Gregory Bock and Jamie Goode]
| Generation and effector functions of regulatory lymphocytes / / [editors, Gregory Bock and Jamie Goode] |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, c2003 |
| Descrizione fisica | 1 online resource (327 p.) |
| Disciplina | 571.9/6 |
| Altri autori (Persone) |
BockGregory
GoodeJamie |
| Collana | Novartis Foundation symposium |
| Soggetto topico |
Lymphocytes
T cells Immune response - Regulation |
| ISBN |
1-280-27406-9
9786610274062 0-470-87161-X 0-470-87162-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
GENERATION AND EFFECTOR FUNCTIONS OF REGULATORY LYMPHOCYTES; Contents; Participants; Chair's introduction; Thymic generation and selection of CD25(+)CD4(+) regulatory T cells: implications of their broad repertoire and high self-reactivity for the maintenance of immunological self-tolerance; Discussion; Control of T cell activation by CD4(+)CD25(+) suppressor T cells; Discussion; Regulation of experimental autoimmune encephalomyelitis (EAE) by CD4(+)CD25(+) regulatory T cells; Discussion; The role of CD28 and CTLA4 in the function and homeostasis of CD4(+)CD25(+) regulatory T cells
DiscussionCD4(+)CD25(+) regulatory cells from human peripheral blood express very high levels of CD25 ex vivo; Discussion; Control of immune pathology by regulatory T cells; Discussion; General discussion I TGFB; Type 1 T regulatory cells and their relationship with CD4(+)CD25(+) T regulatory cells; Discussion; (PRO)insulin-specific regulatory T cells; Discussion; CD1d-restricted NKT regulatory cells: functional genomic analyses provide new insights into the mechanisms of protection against Type 1 diabetes; Discussion Seven surprises in the TCR-centred regulation of immune responsiveness in an autoimmune systemDiscussion; Regulatory cells in transplantation; Discussion; CD4(+) regulatory T cells in chronic viral infection; Discussion; General discussion II; Modulation of T cell responses after cross-talk between antigen presenting cells and T cells: a give-and-take relationship; Discussion; Dendritic cells: controllers of the immune system and a new promise for immunotherapy; Discussion; Regulation of viral and autoimmune responses; Discussion; General discussion III Active immune regulation Notch signalling in the peripheral immune systemDiscussion; CD3 antibody treatment stimulates the functional capability of regulatory T cells; Discussion; The role of dendritic cells in regulating mucosal immunity and tolerance; Discussion; Index of contributors; Subject index |
| Record Nr. | UNINA-9910877481903321 |
| Hoboken, N.J., : Wiley, c2003 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Human immunology
| Human immunology |
| Pubbl/distr/stampa | New York, NY, : Elsevier Science Pub. Co |
| Disciplina | 616.07/9/05 |
| Soggetto topico |
Immunology
Immune response - Regulation HLA histocompatibility antigens Histocompatibility Immunology - Periodicals Allergy and Immunology Immunologie - Périodiques Réaction immunitaire - Régulation Antigènes HLA Immunologie Histocompatibilité |
| Soggetto genere / forma |
Periodical
periodicals. Periodicals. Périodiques. |
| ISSN | 1879-1166 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNISA-996218517603316 |
| New York, NY, : Elsevier Science Pub. Co | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Human immunology
| Human immunology |
| Pubbl/distr/stampa | New York, NY, : Elsevier Science Pub. Co |
| Disciplina | 616.07/9/05 |
| Soggetto topico |
Immunology
Immune response - Regulation HLA histocompatibility antigens Histocompatibility Allergy and Immunology Immunologie - Périodiques Réaction immunitaire - Régulation Antigènes HLA Immunologie Histocompatibilité |
| Soggetto genere / forma |
Periodical
periodicals. Periodicals. Périodiques. |
| ISSN | 1879-1166 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910146786803321 |
| New York, NY, : Elsevier Science Pub. Co | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Immune modulating agents / / edited by Thomas F. Kresina
| Immune modulating agents / / edited by Thomas F. Kresina |
| Edizione | [1st.] |
| Pubbl/distr/stampa | Boca Raton : , : CRC Press, , 2020 |
| Descrizione fisica | 1 online resource (xiv, 557 pages) : illustrations |
| Disciplina | 616.079 |
| Soggetto topico |
Immune response - Regulation
Biological response modifiers |
| ISBN |
1-00-306467-1
1-000-14597-2 1-000-11012-5 1-003-06467-1 0-585-38885-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | pt. I. Immunomodulation -- pt. II. Immunomodulating agents in disease -- pt. III. Immunomodulating agents in therapy. |
| Record Nr. | UNINA-9910585983003321 |
| Boca Raton : , : CRC Press, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Immune Response Activation and Immunomodulation / / Rajeev K. Tyagi, Prakash S. Bisen, editors
| Immune Response Activation and Immunomodulation / / Rajeev K. Tyagi, Prakash S. Bisen, editors |
| Autore | Prakash S. Bisen |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | IntechOpen, 2019 |
| Descrizione fisica | 1 online resource (xii, 165 pages) : illustrations |
| Disciplina | 616.079 |
| Soggetto topico |
Immune response - Regulation
Immune system |
| Soggetto non controllato |
Life Sciences
Immunology and Microbiology Pure Immunology |
| ISBN |
1-83962-135-4
1-78985-152-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910326250903321 |
Prakash S. Bisen
|
||
| IntechOpen, 2019 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The immune synapse as a novel target for therapy [[electronic resource] /] / Luis Graca, editor
| The immune synapse as a novel target for therapy [[electronic resource] /] / Luis Graca, editor |
| Edizione | [1st ed. 2008.] |
| Pubbl/distr/stampa | Basel, : Birkhäuser, c2008 |
| Descrizione fisica | 1 online resource (203 p.) |
| Disciplina | 616.079 |
| Altri autori (Persone) | GracaLuis, MD. |
| Collana | PIR (Series) |
| Soggetto topico |
Immune response - Molecular aspects
Immune response - Regulation Synapses |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-281-14091-0
9786611140915 3-7643-8296-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | The immune synapse and T cell activation: regulation by chemokines -- The induction of regulatory T cells by targeting the immune synapse -- Infiltrating the immunological synapse: prospects for the use of altered peptide ligands for the treatment of immune pathology -- Targeting CD4 for the induction of dominant tolerance -- Anti-CD3: from T cell depletion to tolerance induction -- Immune modulation by CD40L blockade -- CTLA-4-immunoglobulin and indoleamine 2,3-dioxygenase in dominant tolerance -- Adhesion molecules as therapeutic targets -- E3 ubiquitin ligases and immune tolerance: Targeting the immune synapse from within? -- FOXP3 biochemistry will lead to novel drug approaches for vaccines and diseases that lack suppressor T cells -- Transforming growth factor-?: From its effect in T cell activation to a role in dominant tolerance -- From mice to men: the challenges of developing tolerance-inducing biological drugs for the clinic. |
| Record Nr. | UNINA-9910458653103321 |
| Basel, : Birkhäuser, c2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The immune synapse as a novel target for therapy / / Luis Graca, editor
| The immune synapse as a novel target for therapy / / Luis Graca, editor |
| Edizione | [1st ed. 2008.] |
| Pubbl/distr/stampa | Basel, : Birkhauser, c2008 |
| Descrizione fisica | 1 online resource (203 p.) |
| Disciplina | 616.079 |
| Altri autori (Persone) | GracaLuis, MD. |
| Collana | PIR (Series) |
| Soggetto topico |
Immune response - Molecular aspects
Immune response - Regulation Synapses |
| ISBN |
1-281-14091-0
9786611140915 3-7643-8296-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | The immune synapse and T cell activation: regulation by chemokines -- The induction of regulatory T cells by targeting the immune synapse -- Infiltrating the immunological synapse: prospects for the use of altered peptide ligands for the treatment of immune pathology -- Targeting CD4 for the induction of dominant tolerance -- Anti-CD3: from T cell depletion to tolerance induction -- Immune modulation by CD40L blockade -- CTLA-4-immunoglobulin and indoleamine 2,3-dioxygenase in dominant tolerance -- Adhesion molecules as therapeutic targets -- E3 ubiquitin ligases and immune tolerance: Targeting the immune synapse from within? -- FOXP3 biochemistry will lead to novel drug approaches for vaccines and diseases that lack suppressor T cells -- Transforming growth factor-?: From its effect in T cell activation to a role in dominant tolerance -- From mice to men: the challenges of developing tolerance-inducing biological drugs for the clinic. |
| Record Nr. | UNINA-9910823074603321 |
| Basel, : Birkhauser, c2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Soggetto topico
-
Immune response - Regulation
(24)
- T cells (9)
- Cytokines (3)
- Diseases (3)
- Health (3)